The use of intravenous aminobisphosphonates for the treatment of Paget's disease of bone

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 9, 2009, Pages 1052-1063

  Gennari, Luigi ^a   Merlotti, Daniela ^b   Mossetti, Giuseppe ^b   Rendina, Domenico ^b   De Paola, Vincenzo ^b   Martini, Giuseppe ^b   Nuti, Ranuccio ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b NONE

Author keywords

Bisphosphonates; Bone turnover; Neridronate; Paget's disease of bone; Pamidronate; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; AMINOBISPHOSPHONIC ACID DERIVATIVE; ANTIBIOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; NARCOTIC ANALGESIC AGENT; NERIDRONIC ACID; PAMIDRONIC ACID; PARACETAMOL; PLACEBO; RISEDRONIC ACID; TILUDRONIC ACID; UNCLASSIFIED DRUG; VITAMIN D; ZOLEDRONIC ACID; 6 AMINO 1 HYDROXYHEXANE 1,1 DIPHOSPHONATE; 6-AMINO-1-HYDROXYHEXANE-1,1-DIPHOSPHONATE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ACUPUNCTURE; ALBERS SCHOENBERG DISEASE; ARTHRITIS; BLOOD DISEASE; BONE DISEASE; BONE MALFORMATION; BONE PAIN; BONE STRUCTURE; BONE TURNOVER; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; ELECTROSTIMULATION; ESOPHAGUS DISEASE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; HYPERPARATHYROIDISM; HYPOCALCEMIA; JAW OSTEONECROSIS; KIDNEY DYSFUNCTION; MULTIPLE MYELOMA; MUSCULOSKELETAL PAIN; NEPHROTOXICITY; NERVE STIMULATION; NONHUMAN; OSTEOGENESIS IMPERFECTA; OSTEOMALACIA; OSTEOPOROSIS; PAGET BONE DISEASE; PATIENT COMPLIANCE; PHYSICAL DISABILITY; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TACHYPHYLAXIS; TREATMENT INDICATION; TREATMENT RESPONSE; WALKING AID; ANIMAL; CHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; IMIDAZOLES; INJECTIONS, INTRAVENOUS; OSTEITIS DEFORMANS;

EID: 70349576200     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709788922683     Document Type: Review

References (105)

1. Paget, J. On a form of chronic inflammation of bones (osteitis deformans). Med. Chir. Trans., 1877, 60, 37-63.
2. Altman, R.D. Paget disease of bone. In Disorders of Bone and Mineral Metabolism. Coe, F.L.; Favus, M.J. Ed., Raven Press; New York, 1991, 1027-1064.
3. Barker, D.J. The epidemiology of Paget disease. Metab. Bone Dis. Relat. Res., 1981, 3, 231-233.
4. Detheridge, F.M.; Guyer, P.B.; Barker, D.J. European distribution of Paget disease of bone. Br. Med. J., 1982, 285, 1005-1008. (Pubitemid 12018489)
5. Cooper, C.; Harvey, N.C.; Dennison, E.M.; van Staa, T.P. Update on the epidemiology of paget disease of bone. J. Bone Miner. Res., 2006, 21, P3-8.
6. van Staa, T.P.; Selby, P.; Leufkens, H.G.; Lyles, K.; Sprafka, J.M.; Cooper, C. Incidence and natural history of Paget disease of bone in England and Wales. J. Bone Miner. Res., 2002, 17, 465-471.
7. Barker, D.J.; Chamberlain, A.T.; Guyer, P.B.; Gardner, M.J. Paget disease of bone: the Lancashire focus. Br. Med. J., 1980, 280, 1105-1107. (Pubitemid 10107413)
8. Cooper, C.; Schafheutle, K.; Dennison, E.; Kellingray, S.; Guyer, P.; Barker, D. The epidemiology of Paget disease in Britain: Is the prevalence decreasing? J. Bone Miner. Res., 1999, 14, 192-197. (Pubitemid 29066243)
9. Cundy, T.; McAnulty, K.; Wattie, D.; Gamble, G.; Rutland, M.; Ibbertson, H.K. Evidence for secular change in Paget disease. Bone, 1997, 20, 69-71.
10. Roodman, G.D.; Windle, J.J. Paget disease of bone. J. Clin. Invest., 2005, 115, 200-208.
11. Robey, P.G.; Bianco, P. The role of osteogenic cells in the pathophysiology of Paget disease. J. Bone Miner. Res., 1999, 14, 9-16. (Pubitemid 29455792)
12. Krane, S. Paget disease of bone. Calcif. Tissue Int., 1986, 38, 309-317.
13. Reddy, S.V.; Menaa, C.; Singer, F.R.; Demulder, A.; Roodman, G.D. Cell biology of Paget disease. J. Bone Miner. Res., 1999, 14, 3-8.
14. Demulder, A.; Takahashi, S.; Singer, F.R.; Hosking, D.J.; Roodman, G.D. Evidence for abnormalities in osteoclast precursors and the marrow microenvironment in Paget disease. Endocrinology, 1993, 133, 1978-1982.
15. Yasuda, H.; Shima, N.; Nakagawa, N.; Yamaguchi, K.; Kinosaki, M.; Mochizuchi, S.; Tomoyasu, A.; Yano, K.; Goto, M.; Murakami, A.; Tsuda, E.; Morinaga, T.; Higashio, K.; Udagawa, N.; Takahashi, N.; Suda, T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis- inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA, 1998, 95, 3597-3602. (Pubitemid 28173173)
16. Shankar, S.; Hosking, D.J. Biochemical assessment of Paget's disease of bone. J. Bone Miner. Res. , 2006, 21(Suppl 2), P22-7
17. Merlotti, D.; Gennari, L.; Galli, B.; Martini, G.; Calabrò, A.; De Paola, V.; Ceccarelli, E.; Nardi, P.; Avanzati, A.; Nuti, R. Characteristics and familial aggregation of Paget disease of bone in Italy. J Bone Miner. Res., 2005, 20, 1356-1364.
18. Poncelet, A. The neurologic complications of Paget disease. J. Bone Miner. Res., 1999, 14, 88-91.
19. Ooi, C.G.; Fraser, W.D. Paget disease of bone. Postgrad. Med., 1997, 73, 69-74.
20. Lyles, K.W.; Siris, E.S.; Singer, F.R.; Meunier, P.J. A clinical approach to diagnosis and management of Paget disease of bone. J. Bone Miner. Res., 2001, 16, 1379-1387. (Pubitemid 32675190)
21. Strickenberger, S.A.; Schulman, S.P.; Hutchins, G.M. Association of Paget disease of bone with calcific aortic valve disease. Am. J. Med., 1987, 82, 953-956.
22. Huvos, A.G. Osteogenic sarcoma of bones and soft tissues in older persons. A clinico-pathologic analysis of 117 patients older than 60 years. Cancer, 1986, 57, 1442-1449
23. Jacobs, T.P.; Michelsen, J.; Polay, J.S.; D Adamo, A.C., Canfield, R.E. Giant cell tumor in Paget disease of bone: familial and geographic clustering. Cancer, 1979, 44, 742-747. (Pubitemid 10233788)
24. Siris, E.S.; Feldman, F. Natural history of untreated Paget disease of the tibia. J. Bone Miner. Res., 1997, 12, 691-692. (Pubitemid 27155230)
25. Meunier, P.J.; Vignot, E. Therapeutic strategy in Paget disease of bone. Bone, 1995, 17, 489S-491S.
26. Bickerstaff, D.R.; Douglas, D.L.; Burke, P.H.; O Doherty, D.P.; Kanis, J.A. Improvement in facial deformity of Paget disease treated with diphosphonates. J. Bone Joint. Surg. Br., 1990, 72, 132-136.
27. Murdin, L.M.; Yeoh, L.H. Hearing loss treated with pamidronate. J. R. Soc. Med., 2005, 98, 272-274.
28. Selby, P.L.; Davie, M.W.J.; Ralston, S.H.; Stone, M.D. Guidelines on the management of Paget disease of bone. Bone, 2002, 31, 366-373. (Pubitemid 35299615)
29. Siris, E.S.; Lyles, K.W.; Singer, F.R.; Meunier, P.J. Medical management of Paget disease of bone: implications for treatment and review of current therapies. J. Bone Miner. Res., 2006, 21, P94-P97.
30. Papapoulos, S.E.; Eekhoff, E.M.; Zwinderman, A.H. Acquired resistance to bisphosphonates in paget disease of bone. J. Bone Miner. Res., 2006, 21, P88-P91.
31. Russell, G. Bisphosphonates from bench to bedside. Ann. N.Y. Acad. Sci., 2006, 1068, 367-401.
32. Rogers, M.J. New insights into the molecular mechanisms of action of bisphosphonates. Curr. Pharm. Des., 2003, 11, 196-214.
33. Reszka, A.A.; Rodan, G.A. Nitrogen-containing bisphosphonate mechanism of action. Mini Rev. Med. Chem., 2004, 4, 711-719.
34. Canfield, R.E.; Rosner, W.; Skinner, J.; McWhorter, J.; Resnick, L.; Feldman, F.; Kammerman , S.; Ryan, K.; Kunigonis, M.; Bohne, W. Diphosphonate therapy of Paget disease of bone. J. Clin. Endocrinol. Metab., 1977, 44, 96-106. (Pubitemid 8030788)
35. Siris, E.S.; Jacobs, T.P.; Canfield, R.E. Paget disease of bone. Bull. N. Y. Acad. Med., 1980, 56, 285-304.
36. Siris, E.; Canfield, R.; Jacobs, T.; Stoddart, K.; Spector, T. Clinical and biochemical effects of EHDP in Paget disease of bone: patterns of response to initial treatment and to long-term therapy. Metab. Bone Dis. Relat. Res., 1981, 3, 301-308.
37. Roux, C.; Gennari, C.; Farrerons, J.; Devogelaer, J.P.; Mulder, H.; Kruse, H.P.; Picot, C.; Titeux, L.; Reginster, J.Y.; Dougados, M. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget disease of bone. Arthritis Rheum., 1995, 38, 851-885.
38. Delmas, P.D.; Meunier, P.J. The management of Paget disease of bone. N. Engl. J. Med., 1997, 336: 558-566.
39. McClung, M.R.; Tou, C.P.K.; Goldstein, N.H.; Picot, C. Tiludronate therapy for Paget disease of bone. Bone, 1995, 17, 493S-496S.
40. Siris. E.S.; Weinstein, R.S.; Altman, R.; Conte, J.M.; Favus, M.; Lombardi, A.; Lyles, K.; McIlwain, H.; Murphy, W.A.; Reda, C.; Rude, R.; Seton, M.; Tiegs, R.; Thompson, D.; Tucci, J.R.; Yates, A.J.; Zimering, M. Comparative study of alendronate vs. etidronate for the treatment of Paget disease of bone. J. Clin. Endocrinol. Metab., 1996, 81, 961-967. (Pubitemid 26083954)
41. Reid, I.; Nicholson, G.C.; Weinstein, R.S.; Hosking, D.J.; Cundy, T.; Kotowicz, M.A.; Murphy, W.A. Jr; Yeap, S.; Dufresne, S.; Lombardi, A.; Musliner, T.A.; Thompson, D.E.; Yates, A.J. Biochemical and radiologic improvement in Paget disease of bone treated with alendronate: A randomized placebo-controlled trial. Am. J. Med., 1996, 101, 341-348.
42. Miller, P.D.; Brown, J.P.; Siris, E.S.; Hoseyni, M.S.; Axelrod, D.W.; Bekker, P.J. A prospective, multicenter, randomized, double- blind comparison of risedronate and etidronate in the treatment of Paget disease of bone. Am. J. Med., 1999, 106, 513-520.
43. Frijlink, W.B.; Bijvoet, O.L.M.; teVelde, J.; Heynen, G. Treatment of Paget disease with 3-amino-1-hydroxypropylidene-l,l-biphosphonate (APD). Lancet, 1979, 1, 799-803.
44. Walsh, J.P.; Attewell, R.; Stuckey, B.G.A.; Hooper, M.J.; Wark, J.D.; Fletcher, S.; Ferrari, V.; Eisman, J.A. Treatment of Paget disease of bone: A survey of clinical practice in Australia. Bone, 2008, 42, 1219-1225.
45. Harinck, H.I.; Papapoulos, S.E.; Blanksma, H.J.; Moolenaar, A.J.; Vermeij, P.; Bijvoet, O.L. Paget disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). BMJ, 1987, 295, 1301-1305.
46. Joshua, F.; Epstein, M.; Major, G. Bisphosphonate resistance in paget disease of bone. Arthritis Rheum., 2003, 48, 2321-2323. (Pubitemid 36959214)
47. Walsh, J.P.; Ward, L.C.; Stewart, G.O.; Will, R.K.; Criddle, R.A.; Prince, R.L.; Stuckey, B.G.; Dhaliwal, S.S.M.; Bhagat, C.I.M.; Retallack, R.W.; Kent, G.N.; Drury, P.J.; Vasikaran, S.; Gutteridge, D.H. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget disease of bone. Bone, 2004, 34, 747-754.
48. Wimalawansa, S.J.; Gunasekara, R.D. Pamidronate is effective for Paget disease of bone refractory to conventional therapy. Calcif. Tissue Int., 1993, 53, 237-241.
49. Gutteridge, D.H.; Retallack, R.W.; Ward, L.C.; Stuckey, B.G.; Stewart, G.O.; Prince, R.L.; Kent, G.N.; Bhagat, C.I.; Price, R.I.; Thompson, R.I.; Nicholson, G.C. Clinical, biochemical, hematalogic, and radiographic responses in Paget disease following intravenous pamidronate disodium: a 2-year study. Bone, 1996, 19, 387-394.
50. Trombetti, A.; Arlot, M.; Thevenon, J.; Uebelhart, B.; Meunier, P.J. Effect of multiple intravenous pamidronate courses in Paget disease of bone. Rev. Rhum. (Engl Ed), 1999, 66, 467-476.
51. Gallacher, S.J.; Boyce, B.F.; Patel, U.; Jenkins, A.; Ralston, S.H.; Boyle, I.T. Clinical experience with pamidronate in the treatment of Paget disease of bone. Ann. Rheum. Dis., 1991, 50, 930-933.
52. Stone, M.D.; Hawthorne, A.B.; Kerr, D.; Webster, G.; Hosking, D.J. Treatment of Paget disease with intermittent low-dose infusions of disodium pamidronate (APD). J. Bone Miner. Res., 1990, 5, 1231-1235.
53. Bombassei, G.J.; Yocono, M.; Raisz, L.G. Effects of intravenous pamidronate therapy on Paget disease of bone. Am. J. Med. Sci., 1994, 308, 226-233. (Pubitemid 24355589)
54. Stuckey, B.G.; Gutteridge, D.H.; Stewart, G.O.; Prince, R.L.; Ward, L.C.; Kent, G.N.; Prince, R.I.; Retallack, R.W.; Bhagat, C.I.; Nicholson, G.C.; Thompson, R.I. Intravenous pamidronate in Paget disease--response is dependent on radiographic and biochemical severity. Semin. Arthritis Rheum., 1994, 23, 286.
55. Cundy, T.; Wattie, D.; King, A.R. High-dose pamidronate in the management of resistant Paget disease. Calcif. Tissue Int., 1996, 58, 6-8. (Pubitemid 26028371)
56. Gutteridge, D.H.; Ward, L.C.; Stewart, G.O.; Retallack, R.W.; Will, R.K.; Prince, R.L.; Criddle, A.; Bhagat, C.I.; Stuckey, B.G.; Price, R.I.; Kent, G.N.; Faulkner, D.L.; Geelhoed, E.; Gan, S.K.; Vasikaran, S. Paget disease: acquired resistance to one aminobisphosphonate with retained response to another. J. Bone Miner. Res., 1999, 14, 79-84. (Pubitemid 29455804)
57. Lyles, K.W. What is "resistance" in Paget disease of bone? Arthritis Rheum., 2003, 48, 2097-2099.
58. Merlotti, D.; Gennari, L.; Martini, G.; Valleggi, F.; De Paola, V.; Avanzati, A.; Nuti, R. Comparison of different intravenous bisphosphonate regimens for paget disease of bone. J. Bone Miner. Res., 2007, 22, 1510-1517. (Pubitemid 351229321)
59. Tucci, J.R.; Bontha, S. Intravenously administered pamidronate in the treatment of Paget disease of bone. Endocr. Pract., 2001, 7, 423-429. (Pubitemid 33130655)
60. Cantrill, J.A., Anderson, D.C. Treatment of Paget disease of bone. Clin. Endocrinol. (Oxf), 1990, 32, 507-518.
61. Adamson, B.B.; Gallacher, S.J.; Byars, J.; Ralston, SH.; Boyle, I.T.; Boyce, B.F. Mineralization defects with pamidronate therapy for Paget disease. Lancet, 1993, 342, 1459-1460. (Pubitemid 24000292)
62. Boyce, B.F.; Adamson, B.B.; Gallacher, S.J.; Byars, J.; Ralston, S.H.; Boyle, I.T. Mineralization defects after pamidronate for Paget disease. Lancet, 1994, 343, 1231-1232.
63. Buckler, H.M.; Mercer, S.J.; Davison, C.E.; Hollis, S.; Richardson, P.C.; Anderson, D.G. Evaluation of adverse experiences related to pamidronate infusion in Paget disease of bone. Ann. Rheum. Dis., 1998, 57, 572.
64. Nicolin, V.; Bareggi, R.; Baldini, G.; Bortul, R.; Martinelli, B.; Narducci, P. Effects of neridronic acid on osteoclasts derived by physiological dual-cell cultures. Acta Histochem., 2007, 109, 397-402. (Pubitemid 47496173)
65. Spreafico, A.; Freudiani, B.; Capperucci, C.; Gambera, D.; Ferrata, P.; Baldi, F.; Chellini, F.; Piccolini, S.; Bocchi, L.; Marcolongo, R. Anabolic effects and inhibition of interleukin 6 production induced by neridronate on human osteoblasts. Reumatismo, 2006, 58, 288-300. (Pubitemid 46795028)
66. Braga, V.; Gatti, D.; Colapietro, F.; Battaglia, E.; Rigetti, D.; Prizzi, R.; Rossini, M.; Adami, S. Intravenous intermittent neridronate in the treatment of postmenopausal osteoporosis. Bone, 2003, 33, 342-345. (Pubitemid 37114940)
67. D Eufemia, P.; Finocchiaro, R.; Celli, M.; Zambiano, A.; Tetti, M.; Villani, C.; Persiani, P.; Mari, E.; Zicari, A. High levels of serum prostaglandin e2 in children with osteogenesis imperfecta are reduced by neridronate treatment. Pediatr. Res., 2008, 63, 203-206.
68. Magno, C.; Inastasi, G.; Morabito, N.; Gaudio, A.; Malsano, D.; Franchina, F.; Galì, A.; Frisina, N.; Melloni, D. Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate. Eur. Urol., 2005, 47, 575-581. (Pubitemid 40521898)
69. Pittari, G.; Costi, D.; Raballo, M.; Maulucci, L.; Baroni, M.C.; Mangoni, M. Intravenous neridronate for skeletal damage treatment in patients with multiple myeloma. Acta Biomed., 2006, 77, 81-84. (Pubitemid 44884937)
70. Atkins, R.M.; Yates, A.J.; Gray, R.E.; Urwin, G.H.; Hamdy, N.A.; Beneton, M.N.; Rosini, S.; Kanis, J.A. Aminohexane disphosphonate in the treatment of Paget disease of bone. J. Bone Miner. Res., 1987, 2, 273-279.
71. Delmas, P.; Chapuy, M.C.; Edouard, C.; Meunier, P.J. Beneficial effects of aminohexane bisphosphonate in patients with Paget disease of bone resistant to sodium etidronate. Am. J. Med., 1987, 83, 276-282.
72. McCloskey, E.V.; Yates, A.J.P.; Beneton, M.N.C.; Galloway, G.; Harris, S.; Kanis, J.A. Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man. Bone, 1987, 8, S35-S41. (Pubitemid 18047655)
73. Coulton, L.A.; Preston, C.J.; Couch, M.; Kanis, J.A. An evaluation of serum osteocalcin in Paget disease of bone and its response to diphosphonate treatment. Arthrit. Rheum., 1988, 31, 1142-1147.
74. Filipponi, P.; Cristallini, S.; Policani, G.; Casciari, C.; Gregorio, F. Paget disease of bone: benefits of neridronate as a first treatment and in cases of relapse after clodronate. Bone, 1998, 23, 543-548. (Pubitemid 28529459)
75. Adami, S.; Bevilacqua, M.; Broggini, M.; Filipponi, P.; Ortolani, S.; Palummeri, E.; Ulivieri, F.; Nannipieri, F.; Braga, V. Short-term intravenous therapy with Neridronate in Paget disease. Clin. Exp. Rheumatol., 2002, 20, 55-58. (Pubitemid 34213733)
76. Nancollas, G.H.; Tang, R.; Phipps, R.J.; Henneman, Z.; Gulde, S.; Wu, W.; Mangood, A.; Russell, R.G.; Ebetino, F.H. Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite. Bone, 2006, 38, 617-627.
77. Dunford, J.E.; Thompson, K.; Coxon, F.P.; Luckman, S.P.; Hahn, F.M.; Poulter, C.D.; Ebetino, F.H.; Rogers, M.J. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen containing bisphosphonates. J. Pharmacol. Exp. Ther., 2001, 296, 235-242.
78. Green, J.R.; Rogers, M.J. Pharmacologic profile of zoledronic acid: A highly potent inhibitor of bone resorption. Drug. Dev. Res., 2002, 55, 210-224.
79. Body, J.J. Clinical research update: zoledronate. Cancer, 1997, 80, 1699-1701.
80. Green, J.R.; Muller, K.; Jaeggi, K.A. Preclinical pharmacology of CGP 42446, a new, potent, heterocyclic bisphosphonate compound. J. Bone Miner. Res., 1994, 9, 745-751.
81. Green, J.R.; Seltenmeyer, Y.; Jaeggi, K.A.; Widler, L. Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models. Pharmacol. Toxicol., 1997, 80, 225-230. (Pubitemid 27208453)
82. Arden-Cordone, M.; Siris, E.S.; Lyles, K.W.; Knieriem, A.; Newton, R.A.; Schaffer, V.; Zelenakas, K. Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget disease of bone. Calcif. Tissue Int. 1997, 60, 415-418. (Pubitemid 27183891)
83. Buckler, H.; Fraser, W.; Hosking, D.; Ryan, W.; Maricic, MJ.; Singer, F.; Davie, M.; Fogelman, I.; Birbara, C.A.; Moses, A.M.; Lyles, K.; Selby, P.; Richardson, P.; Seaman, J.; Zelenakas, K.; Siris, E. Single infusion of zoledronate in Paget disease of bone: a placebo- controlled, dose-ranging study. Bone, 1999, 24, 81S-85S. (Pubitemid 29202004)
84. Reid, I.R.; Miller, P.; Lyles, K.; Fraser, W.; Brown, J.P.; Saidi, Y.; Mesenbrink, P.; Su, G.; Pak, J., Zelenakas, K.; Luchi, M.; Richardson, P.; Hosking, D. Comparison of a single infusion of zoledronic acid with risedronate for Paget disease. N. Engl. J. Med., 2005, 353, 898-908. (Pubitemid 41247929)
85. Hosking, D.; Lyles, K.; Brown, J.P.; Fraser, W.D.; Miller, P.; Curiel, M.D.; Devogelaer, J.P.; Hooper, M.; Su, G.; Zelenakas, K.; Pak, J.; Fashola, T.; Saidi, Y.; Eriksen, E.F.; Reid, I.R. Long-term control of bone turnover in Paget disease with zoledronic acid and risedronate. J. Bone Miner. Res., 2007, 22, 142-148.
86. Merlotti, D.; Gennari, L.; Valleggi, F.; De Paola, V.; Martini, G.; Avanzati, A.; Nuti, R. Long-term effects of single zoledronate or neridronate infusion in Paget's disease of bone. J. Bone Miner. Res., 2007, 22(suppl.1), S221(M478).
87. Garnero, P.; Christgau, S.; Delmas, P.D. The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget disease of bone. Bone, 2001, 28, 461-464.
88. Podworny, N.V.; Kandel, R.A.; Renlund, R.C.; Grynpas, M.D. Partial chondroprotective effect of zoledronate in a rabbit model of inflammatory arthritis. J. Rheumatol., 1999, 26, 1972-1982.
89. McClung, M.; Recker, R.; Miller, P.; Fiske, D.; Minkoff, J.; Kriegman, A.; Zhou, W.; Adera, M.; Davis, J. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone, 2007, 41, 122-128. (Pubitemid 46901056)
90. Thompson, K.; Rogers, M.J. Bisphosphonates and γ,δ T-cells: new insights into old drugs. Bonekey-Osteovision, 2006, 3, 5-13.
91. Thompson, K.; Rogers, M.J. Statins prevent bisphosphonateinduced gamma,delta-T-cell proliferation and activation in vitro. J. Bone Miner. Res., 2004, 19, 278-288.
92. Lewiecki, E.M.; Miller, P.D. Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. Expert Opin. Drug Saf., 2007, 6, 663-672. (Pubitemid 351308278)
93. Markowitz, G.S.; Fine, P.L.; Stack, J.I.; Kunis, C.L.; Radhakrishnan, J.; Palecki, W.; Park, J.; Nasr, S.H.; Hoh, S.; Siegel, D.S.; D Agati, V.D. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int., 2003, 64, 281-289.
94. Maerevoet, M.; Martin, C.; Duck, L. Osteonecrosis of the jaw and bisphosphonates. N. Engl. J. Med., 2005, 353, 99-102.
95. Khosla, S.; Burr, D.; Cauley, J.; Dempster, D.W.; Ebeling, P.R.; Felsenberg, D.; Gagel, R.F.; Gilsanz, V.; Guise, T.; Koka, S.; McCauley, L.K.; McGowan, J.; McKee, M.D.; Mohla, S.; Pendrys, D.G.; Raisz, L.G.; Ruggiero, S.L.; Shafer, D.M.; Shum, L.; Silverman, S.L.; Van Poznak, C.H.; Watts, N.; Woo, S.B.; Shane, E. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the american society for bone and mineral research. J. Bone Miner. Res., 2007, 22, 1479-1489. (Pubitemid 351229318)
96. Woo, S.B.; Hellstein, J.W.; Kalmar, J.R. Narrative review: bisphosphonates and osteonecrosis of the jaws. Ann. Intern. Med., 2006, 144, 753-761. (Pubitemid 46780635)
97. Grbic, J.T.; Landesberg, R.; Lin, S.Q.; Mesenbrink, P., Reid, I.R.; Leung, P.C.; Casas, N.; Recknor, C.P.; Hua, Y.; Delmas, P.D.; Eriksen, E.F. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J. Am. Dent. Assoc., 2008, 139, 32-40.
98. Ott, S.M. Ten years of alendronate treatment for osteoporosis in postmenopausal women. N. Engl. J. Med., 2004, 351, 190-192.
99. Odvina, C.V.; Zerwekh, J.E.; Rao, D.S.; Maalouf, N.; Gottschalk, F.A.; Pak, C.Y. Severely suppressed bone turnover: a potential complication of alendronate therapy. J. Clin. Endocrinol. Metab., 2005, 90, 1294-1301.
100. Whyte, M.P.; Wenkert, D.; Clements, K.L.; McAlister, W.H.; Mumm, S. Bisphosphonate-induced osteopetrosis. N. Engl. J. Med., 2003, 349, 457-463.
101. Reid I.R. Zoledronate: Efficacy and Safety. J. Bone Miner. Res., 2006; 21(suppl. 2), P83-P87.
102. Black, D.M.; Delmas, P.D.; Eastell, R.; Reid, I.R.; Boonen, S.; Cauley, J.A.; Cosman, F.; Lakatos, P.; Leung, P.C.; Man, Z.; Mautalen, C.; Mesenbrink, P.; Hu, H.; Caminis, J.; Tong, K.; Rosario- Jansen, T.; Krasnow, J.; Hue, T.F.; Sellmeyer, D.; Eriksen, E.F.; Cummings, S.R. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med., 2007, 356, 1809-1822. (Pubitemid 46698462)
103. Recker, R.R.; Delmas, P.D.; Halse, J.; Reid, I.R.; Boonen, S.; García- Hernandez, P.A.; Supronik, J.; Lewiecki, E.M.; Ochoa, L.; Miller, P.; Hu, H.; Mesenbrink, P.; Hartl, F.; Gasser, J.; Eriksen, E.F. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J. Bone Miner. Res., 2008, 23, 6-16.
104. Lyles, K.W.; Colón-Emeric, C.S.; Magaziner, J.S.; Adachi, J.D.; Pieper, C.F.; Mautalen, C.; Hyldstrup, L.; Recknor, C.; Nordsletten, L.; Moore, K.A.; Lavecchia, C.; Zhang, J.; Mesenbrink, P.; Hodgson, P.K.; Abrams, K.; Orloff, J.J.; Horowitz, Z.; Eriksen, E.F.; Boonen, S. HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. N. Engl. J. Med., 2007, 357, 1799-1809.
105. Devogelaer, J.P.; Bergmann, P.; Body, J.J.; Boutsen, Y.; Goemaere, S.; Kaufman, J.M.; Reginster, J.Y.; Rozenberg, S.; Boonen, S. Belgian Bone Club. Management of patients with Paget disease: a consensus document of the Belgian Bone Club. Osteoporos. Int., 2008, 19, 1109-1117.